However, the failure of developing NFTs in APPNLGF x MAPT dKI mice highlights the challenges of naturally modeling tauopathy that aligns with clinical AD development chronologically, when tauopathy develops decades after amyloidosis. The gene discussed is MAPT; the disease is tauopathy.